Researchers and global health agencies are moving quickly to launch adaptive clinical trials during the latest Ebola outbreak in the Democratic Republic of the Congo, building on lessons learned from previous epidemics and the COVID-19 pandemic. Earlier Ebola treatment trials during the 2014–2016 West Africa outbreak were slow to organize and limited in scope, often concluding after outbreaks had already begun to subside. In contrast, international teams now have pre-approved protocols designed to rapidly test multiple treatments during active outbreaks. Following confirmation of the current Bundibugyo Ebola outbreak in May, researchers prioritized testing the antiviral remdesivir and an experimental antibody treatment known as MBP134, with trial protocols already approved by ethics officials and awaiting final regulatory clearance. Continue reading at Science
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.